SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
王晓静
Lv6
224
1955 积分
2022-01-12 加入
最近求助
最近应助
互助留言
Continuation of Third-Generation Tyrosine Kinase Inhibitors in Second-Line Trials for EGFR-Mutated Non–Small-Cell Lung Cancer: Regulatory Considerations
22天前
已完结
Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses
22天前
已完结
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
22天前
已完结
First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer
22天前
已完结
Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review
22天前
已完结
Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
22天前
已完结
Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells
22天前
已完结
Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis
22天前
已完结
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
22天前
已完结
Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study
22天前
已完结
没有进行任何应助
已找到【积分已退回】
2个月前
已找到【积分已退回】
4个月前
doi错误
4个月前
doi错误
4个月前
求助DOI: 10.3760/cma.j.cn115396-20230301-00042,上传的文献不是求助文章
4个月前
感谢
5个月前
感谢
6个月前
感谢
6个月前
ganxie
11个月前
doi错误
2年前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论